The cytokines IL-1 and TNF-α are involved in inflammation and their production is stimulated by various agents, especially endotoxin (LPS). Here, using the human IL-1 receptor antagonist (IL-1RA) and a new monoclonal antibody (mAb 7F11) to rabbit TNF, the role of endogenous IL-1 and TNF production in acute (3 h) leukocyte (PMNL) recruitment to dermal inflammation in rabbits has been studied. IL-1RA inhibited by 27% the PMNL accumulation in reactions induced by killed Escherichia coli (p < 0.05) but not by LPS. The monoclonal antibody to TNF inhibited by 27% and 38% (p < 0.002) the PMNL accumulation in LPS and E. coli reactions respectively, but a combination of the mAb with IL-1RA was not more effective. Treatment of human umbilical vein endothelium with LPS for 3 h activated endothelium to induce PMNL transendothelial migration in vitro, which was not inhibited by IL-1RA, antibody to TNF-α, IL-1 or to IL-8. In conclusion, TNF and IL-1 may partially mediate acute PMNL infiltration in vivo to LPS and Gram negative bacteria, but there is a major IL-1/TNF independent mechanism, at least in dermal inflammation, which may be due to direct LPS activation of the microvasculature or perhaps the generation of cytokines other than IL-1 and TNF.

Keywords: IL-1, Inflammation, Interleukin, Neutrophil, TNF

Introduction

The acute inflammatory reaction is usually characterized by rapid, early (1–2 h) infiltration of the tissue by polymorphonuclear leukocytes (PMNL) and an increase in vascular permeability. Subsequently, vascular and tissue injury may result. A host of mediators and mediator systems have been implicated in this response, including vasoactive amines, lipids and proteins, some of which are generated by activation of cascade systems such as the complement and coagulation pathways. More recently, some members of the cytokine family of proteins have been found to have inflammatory properties. Among these, interleukin-1 (IL-1) and tumour necrosis factor α (TNF) are synthesized rapidly, especially by monocytes, resident tissue macrophages and to a lesser extent by PMNL, lymphocytes, and connective tissue cells. Both IL-1 and TNF can subsequently active other cells, such as vascular endothelium to become adhesive for PMNL and mononuclear leukocytes, and to induce the synthesis of cytokines directly chemotactic for leukocytes such as IL-8 and monocyte chemotactic protein-1 (MCP-1). Among the cytokines, IL-1 and TNF-α, are likely the earliest cytokines in the cytokine cascade to be synthesized during acute inflammatory reactions.

It is now well recognized that vascular and tissue injury during acute inflammation is in part dependent on the invasion of the involved tissues by PMNL. As part of on-going investigations into the mechanisms regulating PMNL migration into inflammation, an acute dermal inflammation model in rabbits has been used in this study. The role of endogenously produced IL-1 and TNF in the acute PMNL accumulation in dermal inflammatory reactions induced by a variety of agents has been investigated. For this purpose, recombinant human IL-1 receptor antagonist (IL-1RA) and a new monoclonal antibody (mAb) which neutralizes rabbit TNF, were employed to block the activity of endogenously produced rabbit IL-1 and TNF. The results indicate that of the reactions studied, TNF in particular, contributes significantly but only to a minor extent, to the PMNL infiltration during killed Escherichia coli and endotoxin (LPS) induced inflammation.

Materials and Methods

Dermal inflammatory reactions: New Zealand White rabbits of either sex (3–4 kg) had their backs shaved the day before experiments. On the day of study, 51Cr labelled blood leukocytes (see below), were injected i.v. and up to 56 skin sites were injected intradermally (i.d.) (0.2 ml) with inflammatory stimuli in a random pattern using 30-gauge needles as described previously. Three hours later, the
animal was sacrificed with an intravenous (i.v.) overdose of pentobarbital, the skin was removed, and the lesions punctured out using a 16 mm leather punch. Radioactivity in the skin samples was determined in an LKB gamma spectrometer.

Inflammatory stimuli: Recombinant human interleukin-1 (IL-1), which had a specific activity of $4 \times 10^7$ U/mg, was a gift from Dr D. UrDAL (Immunex Corp., Seattle, WA, USA). Recombinant human tumour necrosis factor (TNF-α) (specific activity of $5 \times 10^7$ U/mg) was a gift from Genentech Inc. (South San Francisco, CA, USA). All of these cytokines contained $\leq 1$ ng of endotoxin/mg. Each of the cytokines were diluted immediately before use in 0.1% endotoxin-free human serum albumin (Connaught Labs., Don Mills, Ontario, Canada) in phosphate buffered saline (HSA–PBS). E. coli 0111 lipopolysaccharide (LPS) was from List Biologicals (Campbell, CA). E. coli 018.K1H7, an isolate from an infant with meningitis, was grown in broth culture, killed with formaldehyde, washed, and the number of bacteria were estimated spectrophotometrically as described previously. Zymosan activated plasma (ZAP) was generated as previously by incubation of heparinized (5 U/ml) rabbit plasma for 60 min (37°C) with 5 mg/ml Zymosan A (Sigma Chemical Co., St. Louis, MO, USA) followed by removal of zymosan by centrifugation.

The reversed dermal Arthus reaction was induced by i.v. injection of 10 mg human pyrogen free IgG (Sandoglobulin, Sandoz Pharmaceuticals, Dorval, Quebec, Canada), 1 h prior to i.d. injection of heat inactivated hyperimmune rabbit antiserum to human IgG. Rabbit TNF-α was purified from rabbit macrophage culture supernatants. Briefly, rabbit peritoneal macrophages were harvested, following pentobarbital euthanasia, by peritoneal lavage with 300 ml Tyrode solution (2 U/ml heparin), 5 days following i.p. injection of 35 ml sterile light mineral oil. The cells were adhered in 175 cm² tissue culture flasks (Falcon, Fisher Scientific Co., Dartmouth, Nova Scotia, Canada) for 2 h in RPMI-1640 (Gibco, Grand Island, NY, USA) 5% heat inactivated rabbit serum, then rinsed to remove non-adherent cells. The adherent cells, which were >95% macrophages, were stimulated with LPS (30 ng/ml) in RPMI-1640 for 6 h at 37°C in 5% CO₂. The supernatant was then harvested, dialysed against water, concentrated by lyophilization 100–200-fold and applied to a Superose-12 FPLC column (Pharmacia Fine Chemicals, Dorval, Quebec) equilibrated with 0.3 M NaCl–0.01 M Na₂HPO₄, pH 7. Fractions eluting between 40 and 50 kilodaltons (kDa), were rich in TNF activity as assayed by cytotoxicity for the TNF sensitive L929 mouse fibroblast line. The fractions which eluted between 12 and 20 kDa were devoid of IL-1 activity.

Anticytokine reagents: Highly purified human recombinant interleukin-1 receptor antagonist (IL-1RA) was a kind gift from Dr R. C. Thompson (Synergen Inc., Boulder, CO). The rat mAb 7F11, which neutralized rabbit macrophage TNF-α and lymphocyte derived TNF-β bioactivity, was rat isotype IgG₁ according to a commercially available isotyping kit (Serotec Canada, Toronto, Ontario). This antibody was generated by immunization of AO strain male rats with partially purified TNF-α (40–50 kDa Superose-12 fractions). The immunization protocol consisted of covalently coupling 3–5 μg of protein to 1 cm² pieces of the APT form of Transabind paper (Schleicher and Schuell Ltd, Keene, NH, USA) according to the instructions of the manufacturer. The immobilized antigen was introduced surgically under anaesthesia into the peritoneal cavity of the rats every 10–14 days together with i.p. injection of polyadenosine-polyuridine (800 μg) (Sigma Chemical Co.) as an adjuvant. After a total of four such immunizations, the animals had neutralizing activity in their serum for rabbit TNF-α. After a rest period, one rat was booster immunized by intrasplenic injection of 5 μg of partially purified antigen. Four days later the spleen was removed, and splenocytes were fused with the P3U1 mouse myeloma using polyethylene glycol 1450 (Merck Frosst, Montreal, Quebec) according to standard techniques. Following fusion, the lymphocytes were plated into flat bottom 96-well microtitre plates (NUNC, Gibco) at a density of $2 \times 10^5$ cells/well in Dulbecco Modified Eagle’s Medium (DMEM; Gibco) with non-essential amino acids, Na pyruvate and 10% foetal calf serum (FCS; Hyclone, Logan, UT, USA), into wells containing a mixture of 5 x 10⁵ irradiated mouse thymocytes and splenocytes prepared 24 h previously as feeder cells. Supernatants from hybridoma-containing wells were screened for neutralization of the cytotoxic activity of rabbit TNF-α, and one of the positive hybridomas, 7F11 was cloned by limiting dilution. This mAb neutralized both rabbit macrophage derived TNF-α and mitogen (Con A and PHA) stimulated rabbit lymphocyte derived TNF activity, presumably TNF-β. However, mAb 7F11 was specific for rabbit TNF in that it did not neutralize mouse, rat or human TNF activity. The mAb was purified by affinity chromatography on Protein G Sepharose from cells grown in serum free medium (DMEM supplemented with 2% Nutridoma, Boehringer Mannheim, Montreal, Quebec). Binding of the IgG was at pH 7 in PBS and elution was with 0.1 M glycine–HCl, pH 3.5 followed by pH 2.7 buffers, as recommended by the manufacturer (Pharmacia Fine
Chemicals, Dorval, Quebec). The purified mAb preparation had a titre of 30 000 neutralizing units/ml.

Polyclonal rabbit antibody to human IL-1α and IL-1β and to human TNF-α were kind gifts from Dr C. Dinarello (Tufts University, Boston, MA, USA). Polyclonal goat antibody to human IL-8 was a gift from Sandoz Pharmaceuticals (Vienna, Austria). These antibodies were all neutralizing and were used in a dilution of 1:100 in the in vitro assay system. Neutralizing mAb to human TNF-α was a kind gift from Dr M. Sheppard (Genentech Inc., South San Francisco, CA). It had a neutralizing titre of $8 \times 10^6$ NU/mg.

Measurement of rabbit leucocyte accumulation in dermal inflammation: The quantitation of leucocyte accumulation in dermal inflammatory reactions has been described in detail previously. Briefly, 30 ml of acid-citrated dextrose anticoagulated blood was collected from the rabbit and red blood cells were removed by hydroxyethyl cellulose sedimentation (Fluka Chemical Co., Ronkonkoma, NY). The leucocytes were labelled with Na$_2$CrO$_4$ (Amer sham Inc., Oakville, Ontario), washed with Ca$^{2+}$, Mg$^{2+}$ free Tyrodes' buffer−10% ACD plasma, and injected i.v. just prior to the injection (i.d.) of inflammatory stimuli in skin sites. It has been shown that results with this mixed leucocyte population, labelled with $^{51}$Cr are comparable to that obtained with purified $^{51}$Cr-labelled PMNLs, as long as the leucocyte infiltration into the acute inflammatory lesions is composed of >90% PMNLs and no local haemorrhage in the site occurs. Both of these criteria were met in this work during the period of study of the lesions (3 h). The $^{51}$Cr cpm in the skin lesion was converted to number of PMNLs $\times 10^6$ accumulated/site by standardizing values relative to the response to zymosan activated plasma (ZAP) at $10 \times 10^6$ PMNL/site. This value is based on the mean response ($10 \pm 0.8 \times 10^6$ PMNL/site; SEM) in 30 rabbits, in previous studies in which blood PMNL specific activity (number of PMNL/cpm) was determined after $^{51}$Cr–leucocyte injection, using hydroxyethyl cellulose sedimentation of red cells and Percoll's density gradient purification of the PMNLs. The PMNL specific activity measurement allowed for conversion of $^{51}$Cr content in skin sites to number of PMNL/site as described.

Endothelial cell cultures: Human umbilical vein endothelial cells (HUVE) were obtained using collagenase digestion as described by Jaffe et al. and described in detail previously. Briefly, isolated cells were grown to confluence in gelatin coated flasks in RPMI-1640-20% FCS, supplemented with Endothelial Cell Growth Supplement (25 µg/ml) (Collaborative Research, Lexington, MA), Na pyruvate (1 mM), 2-mercaptoethanol (2ME) (50 µM), heparin (90 µg/ml) and penicillin/streptomycin. HUVE were then gently trypsinized and plated on gelatin–fibroinectin coated polycarbonate filters bearing $3 \mu$m pores in 24-well transwell culture plate inserts (6.5 mm) (Costar Corp., Cambridge, MA). After 6 days of culture in the above medium, endothelium formed a tight monolayer and permeability barrier separating an upper chamber of 100 µl volume from a lower chamber (24-well plate macrowell) containing 600 µl medium as described previously.

Human polymorphonuclear leucocyte purification: Human PMNL were purified from acid citrate dextrose–heparin anticoagulated peripheral venous blood of healthy donors as described previously. Briefly, red cells were sedimented with 6% dextran–saline (Abbott Labs, Montreal, Quebec), leucocyte rich plasma was collected and leucocytes were labelled with Na$_2$CrO$_4$ (Amersham Inc.). PMNLs were then purified by discontinuous Percoll's gradient centrifugation, washed, and resuspended to $3 \times 10^6$ PMNL/ml in RPMI-1640-0.5% HSA-10mM Hepes pH 7.2. This method yielded PMNL of $\geq 95\%$ purity with essentially no red cell contamination and $\geq 98\%$ cell viability.

In vitro PMNL transendothelial migration assay: For assays, HUVE monolayers were handled according to the previously published protocol. In this study, HUVE were stimulated by addition to the lower chamber of various concentrations of LPS in fresh RPMI-1640-10% FCS. After stimulation, monolayers and upper and lower chambers were rinsed, the medium in the lower chamber was exchanged (600 µl) for RPMI-1640-HSA-Heps, and the $^{51}$Cr-PMNL suspension (100 µl) was loaded above the monolayer/filter, and incubated at $37^\circ$C in 5% CO$_2$. After 75 min, migration was stopped by washing the surface above the monolayer with RPMI-1640 to remove non-adherent PMNLs, and the undersurface of the filter was rinsed with 2 ml of ice-cold PBS–0.2% EDTA solution and collected into the lower compartment. The PMNLs which migrated into the lower compartment and those which detached from the undersurface of the filter by washing were lysed with 0.5% Triton X 100 to release the $^{51}$Cr. The $^{51}$Cr content of the lower compartment (medium + PBS–EDTA wash of filter undersurface) represented migrated PMNLs. The results are expressed as a percentage of total added $^{51}$Cr-PMNL in the lower compartment.

Statistical analysis: Statistical analysis of results was performed by 'paired' Student's t-test.
**Results**

**Effect of IL-1 receptor antagonist and antibody to TNF on dermal PMNL infiltration:** In initial experiments the efficacy of recombinant human IL-1 receptor antagonist (IL-1RA) and the mAb to rabbit TNF for blocking the *in vivo* activity of IL-1, and rabbit TNF-α for inducing PMNL accumulation in skin sites were tested. As can be seen in Fig. 1, the injection of 2 ng of recombinant human IL-1α or IL-1β or partially purified rabbit macrophage derived TNF-α, induced marked PMNL accumulation during the first 3 h following i.d. injection. Control injections of HSA–PBS (data not shown) did not cause PMNL accumulation ($0.2 \pm 0.05 \times 10^6$; uninjected skin $0.15 \pm 0.02 \times 10^6$ PMNL per site). These HSA–PBS control values were subtracted from all the values shown in Figs 1 and 2. The simultaneous injection of IL-1RA in a dose of 400 ng per site, together with either IL-1α or IL-1β, almost completely blocked the PMNL accumulation in these sites. Similarly, the addition of mAb to rabbit TNF-α at a dose of 1000 NU per injection site, virtually eliminated the PMNL recruiting activity of 500 units of rabbit TNF-α. In cross inhibition studies the rabbit mAb to TNF did not inhibit the activity of IL-1α or IL-1β for recruiting PMNL into skin sites and vice versa, the human IL-1RA did not inhibit (<10% inhibition) the activity of rabbit TNF-α for inducing PMNL accumulation (not shown).

We next investigated the effects of IL-1RA and mAb to TNF on the accumulation of PMNL in skin sites in the rabbits injected with *E. coli* LPS or killed *E. coli* bacteria. As can be seen on the lower panel in Fig. 1, the leukocyte accumulation induced by LPS was not significantly inhibited by the co-injection of IL-1RA, but was significantly inhibited by mAb to rabbit TNF. The combination of IL-1RA with mAb to TNF did not result in greater inhibition than did mAb to TNF alone. In response to i.d. injection of killed *E. coli*, both IL-1RA and TNF mAb significantly inhibited PMNL accumulation. The combination of IL-1RA with anti-TNF did not inhibit to any greater extent than either alone. In these experiments PMNL accumulation was measured during the first 3 h after i.d. injection of the skin sites, since it has been shown previously that maximum PMNL accumula-
tion occurs during this time in these types of lesions. All combinations of agents were studied in the same rabbit with triplicate or quadruplicate skin sites being injected and statistical analysis was by paired t-test. The dose of IL-1RA and mAb to TNF were optimized for inhibitory activity and the level of inhibition with IL-1RA did not increase upon increasing the dose of IL-1RA to 1000 ng/site or by increasing the mAb dose to 2500 NUm per site.

The effect of IL-1RA and mAb to TNF on three other inflammatory reactions was also studied, namely that induced by i.d. injection of zymosan particles, by the reversed passive Arthus reaction and by ZAP, the active principle of which is C5a des Arg. As shown in Fig. 2, neither IL-1RA nor TNF mAb, nor a combination of both agents inhibited the PMNL accumulation induced by zymosan, ZAP or the Arthus reaction.

The effect of LPS on PMNL migration across vascular endothelium: The migration of PMNL into inflammatory reactions involving IL-1 or TNF, are believed to involve the IL-1 and TNF activation of vascular endothelium to express adhesion molecules for PMNL (reviewed in Ref. 9). Various authors have shown that this activated endothelium not only promotes PMNL adhesion but also PMNL transendothelial migration in vitro. Gram negative bacterial LPS has also been shown to activate endothelium for adhesion of PMNL, but the role of endothelium generated cytokines such as IL-1 or TNF, which could directly activate the endothelium, is not clear. Therefore, the effect of LPS on PMNL interaction directly with vascular endothelial cells was studied using an in vitro system which allows quantitation of PMNL transendothelial migration. Endothelium stimulated with LPS for 3 h resulted in PMNL transendothelial migration as shown in Fig. 3, even though the LPS was removed from the system. An LPS concentration of 0.3 ng/ml was sufficient to induce a maximal response. These results are comparable to previous findings using this system with IL-1 or TNF to activate the endothelium, i.e. 2-4 h of stimulation was optimal for observing PMNL transendothelial migration and periods less than 2 h or longer than 8 h resulted in a decrease in the migration response and not shown. In contrast to the 3 h required to activate endothelium with LPS for supporting this transendothelial migration, PMNL migration across the activated endothelium was rapid, plateauing between 60 to 90 min (not shown) as it was with IL-1 and TNF-α induced PMNL migration reported previously. There was no migration of PMNL in response to any of the concentrations of LPS, in the absence of an endothelial monolayer (and not shown).

It has been shown previously that endothelium can be activated to secrete cytokines such as IL-1, IL-8 and possibly TNF. Therefore, the possibility was examined that the observed effects of LPS may have been due to the endogenous production of one of these cytokines by the endothelium and secondary activation of the endothelium in an autocrine fashion for supporting PMNL migration. Table 1 shows the effects of IL-1RA, and antibodies to IL-1α, IL-1β, TNF-α or IL-8 on LPS stimulated PMNL transendothelial migration. The IL-1RA and antibodies were present during the 3 h LPS stimulation and also during the 75 min PMNL migration, to ensure maximal neutralization of any endogenously produced IL-1, TNF or IL-8.

Table 1. The effect of blocking IL-1, TNF-α and IL-8 on LPS activation of endothelium for PMNL transendothelial migration

| Blocking agent* | % Inhibition of PMNL migration |
|-----------------|-------------------------------|
| IL-1RA (300 ng/ml) | 8.0 |
| mAb TNFα (500 NU/ml) | 7.5 |
| IL-1RA + mAb TNFα | 4.1 |
| anti-IL-8 IgG | 0 |
| IL-1RA + mAb TNFα + anti-IL-8 | 0 |
| polyclonal antisera to IL-1α, IL-1β, + polyclonal antisera to LPS | 7.1 |

* Endothelial monolayers as in Fig. 1 were stimulated with LPS (1 ng/ml) for 3 h in the presence of blocking agents or non-immune serum. After the medium was exchanged prior to the PMNL migration stage, the agents were added back and were present throughout the assay. Polyclonal antisera were used at 1:100 dilution, the predetermined dilution shown to completely block the activities of exogenously added IL-1α, IL-1β, TNFα and IL-8 in separate PMNL transendothelial migration assays (not shown). Similarly the mAb to TNFα and the IL-1RA concentrations completely blocked activation of endothelium by TNFα (10 U/ml) or IL-1α (0.3 ng/ml). Values are means of two experiments for each condition.
Although the antibodies to TNF-α, IL-1, IL-8 and IL-1RA each effectively blocked (>95%) PMNL migration induced by the corresponding exogenously applied cytokine (not shown), the LPS induced activation of endothelium for PMNL transendothelial migration was not significantly inhibited by any of the agents even in combination.

Discussion

The major findings in this study are that IL-1RA and mAb to TNF inhibited PMNL accumulation in inflammatory reactions induced in the dermis by killed E. coli, mAb to TNF inhibited the LPS reaction but, even in combination, these agents only partially inhibited PMNL accumulation in these reactions (Fig. 1). This finding was surprising because IL-1 and TNF-α induce PMNL infiltration into the skin upon intradermal injection and they have synergistic effects.3,4 The results suggest that endogenous production of TNF, at least in dermal inflammation may be more important than IL-1 in LPS and perhaps also in E. coli inflammatory reactions, the latter being partly dependent on LPS shed from the cell wall of the bacteria.24 Another explanation for our results, namely that IL-1RA may not be active as an antagonist of the rabbit IL-1 receptor, is unlikely because the human IL-1RA effectively inhibited the PMNL accumulation in rabbit skin induced by i.d. injection of IL-1α and IL-1β and systemic or local treatment in various species with human IL-1RA has inhibited PMNL infiltration e.g. in LPS induced alveolitis in rats and immune complex colitis in rabbits.10,25,26 The relative lack of effect of IL-1RA in our experiments, in comparison to these other models is unlikely to be due to the doses employed because concentrations of up to 1000 ng per site had no greater inhibitory effect than 200 ng (not shown). Since our mAb neutralizes both α and β species of TNF, it is not possible from these results to conclude that neutralization of TNF-α was responsible for the observed inhibition. However, TNF-β is produced primarily by activated lymphocytes7 of which there are relatively few in the skin during the acute (<3 h) phase of inflammation.27

The differences observed in our experiments with IL-1RA and other inflammation models in which IL-1 appears to play an important role in PMNL recruitment to LPS, for example in peritonitis28 or alveolitis25,29 may be dependent on the tissue and the type of resident cells, especially macrophages available to secrete IL-1, a cytokine which is not readily secreted by all types of macrophages and is released slower or later than TNF-α.3,30,31 Among skin cells, keratinocytes are known to store IL-1 but apparently do not release this except perhaps upon cellular injury.32 Langerhans cells have been shown to secrete IL-1 and TNF-α, and mast cells have recently been shown to secrete preformed stores of TNF-α.3,34 Secretion of TNF-α in skin from these cells may occur more rapidly than of IL-1, perhaps accounting for the greater apparent contribution of TNF to PMNL infiltration in the initial 3 h of the reaction. This conclusion is also supported by the observations that TNF-α is secreted more rapidly (<1 h) than IL-1 in response to LPS injection systemically35 or LPS in the cerebrospinal fluid.36

Additional findings in the dermal inflammation model reported here suggest that neither endogenous production of IL-1 nor TNF contribute to the PMNL infiltration induced by in situ immune complex formation, as in the reversed passive Arthus vasculitis reaction or by zymosan particles (Fig. 2). This is not surprising in that both these reactions are primarily dependent on complement activation15,37 and likely require the generation of C5α des Arg to induce PMNL accumulation. The PMNL recruiting activities of ZAP, which is known to be due to C5α des Arg14 was not inhibited by IL-1RA or by mAb to TNF, as expected and this stimulus served primarily as a negative control and an internal standard.

Finally, the results in Fig. 1 suggest that for LPS and E. coli dermal inflammatory reactions endogenous IL-1 and TNF play minor roles in PMNL recruitment and that additional mechanisms are operative. The killed E. coli reaction is complex and involves, in part, complement activation by the cell wall of the bacterium with the generation of C5α des Arg chemotactic activity as well as the release of LPS from the cell wall of the bacterium, which has no direct PMNL chemotactic properties.24 The response to LPS is also complex. However, two mechanisms can largely be excluded: (a) the LPS used here and at the nanogram concentrations which induce intense inflammatory reactions, has been shown previously not to activate the complement pathway or to generate chemotactic activity for PMNL;24 and (b) the LPS was not directly chemotactic and did not induce PMNL migration in vitro in the absence of an endothelium.24 Endotoxin (LPS) of course is known to be a potent inducer of IL-1 and TNF-α production6,8-35 and via the action of these cytokines could recruit PMNL. In addition, LPS, IL-1 and TNFα all can induce endothelium to produce the PMNL chemotactic cytokine, IL-8, which is also produced by connective tissue cells such as fibroblasts in response to IL-1 or TNF-α (but not LPS).6,8 However, the present findings demonstrate that LPS also can directly activate endothelial cells to promote PMNL transendothelial migration (Fig. 3). This action of LPS, at concentrations ≤1 ng/ml, does not appear to
References

1. Movat HZ. Chemicals — inflammation induced by immune complexes: a model for complement-chemotaxis and PMN-leucocyte-mediated process. In: The Inflammatory Reaction. Amsterdam: Elsevier, 1985: 235-244.

2. Movat HZ. Mediators of the vascular phenomena of acute inflammation. In: The Inflammatory Reaction. Amsterdam: Elsevier, 1985: 77-123.

3. Wankwitz R, Megyesi P, Isekutz A. Synergy between tumour necrosis factor α and interleukin-1 in the induction of polymorphonuclear leucocyte migration during inflammation. J Leukoc Biol 1988; 43: 349-356.

4. Movat HZ, Gybyski ML, Coldia IG, Chau MKW, Dinarello CA. Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. FASEB J 1987; 46: 97-103.

5. Granstein RD, Margolis R, Mizel SB, Sauder DN. In vivo inflammatory activity of epithelial cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse. J Clin Invest 1986; 77: 1020.

6. Larsen C, Zachariassen C, Muktakis N, et al. Proinflammatory cytokines interleukin 1 and tumor necrosis factor induce cytokines that are chemotactic for neutrophils, T cells and monocytes. Proc Clin Biol Res 1990; 349: 419-431.

7. Vassalli P. The pathophysiology of tumor necrosis factors. Am Rev Respir Dis 1992; 10: 411-422.

8. Dinarello CA. The biology of interleukin-1. Clin Immunol 1992; 81: 1-32.

9. Fisher JS, Cooper RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-452.

10. Dinarello CA, Thompson RC. Blocking IL-1: interleukin receptor antibodies. In: Mediators of Inflammation. Vol. 1. Amsterdam: Elsevier, 1992; 353-365.

11. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-340.

12. Isekutz A, Bhimji S, Bortolussi R. Effect of immune serum or polymyxin B on Ehrlichia coli-induced inflammation and vascular injury. J Infect Immun 1982; 36: 548-557.

13. Isekutz AC, Isekutz TB. Quantitation of blood cell accumulation and vascular responses in inflammatory reactions. In: Chang J, Lewis AJ, eds. Modern Methods in Pharmacology. New York: Alan R. Liss Inc., 1989; 129-150.

14. Isekutz AC, Movat HZ, Movat H. Enhanced vascular permeability and hemorrhage-inducing activity of rabbit CSF γ: probable role of polymorphonuclear leucocyte lysosomes. Clin Exp Immunol 1980; 41: 512-520.

15. Movat HZ. Chemotaxis—quantitation and kinetics of the Arthus reaction. Amsterdam: Elsevier, 1985; 245-258.

16. Mathison JC, Wolfson B, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; R1: 1923-1927.

17. Aggarwal BB, Moffit B, Lee SH, Hawkins RN. Chemical and biological properties of human lymphoctytic. In: Goldstein AL, ed. Thymic Hormones and Lymphokines. New York: Plenum Publishing Corporation, 1984; 231-241.

18. Isekutz AC, Morgret P, Isekutz TB. Role for macrophage products in endotoxin-induced polymorphonuclear leucocyte accumulation during inflammation. Lab Invest 1987; 56: 49-59.

19. Hovanessian AG, Galabru J, Riviere Y, Montagnier L. Efficiency of (poly(A)poly(U)) as an adjuvant. Nature 1970; 228: 31-32.

20. Vassalli P. The pathophysiology of tumour necrosis factors. Rev Immunol 1992; 10: 427-452.

21. Harlow E, Lane D. Monoclonal antibodies—producing hybridomas. In: Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory, 1988; 196-228.

22. Jaffe EA, Newstein RL, Becker CG, Minnich CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunological criteria. J Clin Invest 1975; 55: 2747-2752.

23. Mathison JC, Wolfson E, Ulevitch R. Participation of tumour necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; R1: 1923-1927.

24. Isekutz AC, Bhimji S. Role for endotoxin in the leucocyte infiltration accompanying E. coli induced inflammation. In: Infect Immun 1982; 36: 558-566.

25. Ulich TR, Yin S, Guo K, del Castillo J, Elliston SP, Thompson RC. The interferential administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin and IL-1-induced acute inflammation. Am J Pathol 1991; 138: 521-524.

26. Conradi S, Nase CE, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-980.

27. Isekutz AC, Movat HZ. The in vivo quantitation and kinetics of rabbit neutrophil leucocyte accumulation in the skin in response to chemotherapeutic agents and IL-1. Lab Invest 1980; 42: 310-318.

28. McMenany KW, Serpas GJ, Koski KD, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 935-939.

29. Warren JS. Intrapulmonary interleukin 1 mediates acute immune complex arthritis in the rat. Biochem Biophys Acta Commun 1991; 175: 604-610.

30. Isekutz AC, Mrozewsky W, Sedaworska J. Rabbit alveolar macrophages stimulated with endotoxin and lung fragments from endotoxemic rabbits produce a leucocyte infiltration inducing factor that lacks IL-1, TNFα, or chemotactic activity. Exp Lung Res 1991; 17: 303-319.

31. Lonnemann G, Enderes S, van der Meer JW, Cameron GJ, Koch KM, Dinarello CA. Differences in the inflammatory and immune responsiveness of rabbit interleukin 1α, interleukin 1β and tumor necrosis factor from human mononuclear cells. Eur J Immunol 1989; 19: 1531-1536.

32. McKenzie RG, Sauder DN. The role of keratinocyte cytokines in inflammation and immunity. J Invest Dermatol 1990; 95: 1055-1078.

33. Larrick JW, Morchon C, Chiang YT, Shi T. Activated lung macrophages release tumor necrosis factor. J Leukoc Biol 1989; 45: 429-433.

34. Gordon JR, Grilli SJ. Macrophages as a source of both preformed and immunologically inducible TNF-α/interleukin-1. Nature 1990; 346: 274-276.

35. Chenues SW, Tenholis RD, Remick DG, Scieszki WE, Kunkel SL. In vivo biologic and immunohistochemical analysis of interleukin-1 α, β and tumor necrosis factor during experimental endotoxemia. Am J Pathol 1991; 138: 393-402.

36. Waege A, Galstensen A, Kierulf P, et al. Cys-thymopoietin 28-39. J Immunol Methods 1986; 94: 13-17.

37. Waage A, Galstensen A, Shalaby R, Brandtzaeg P, Espevik T. Local production of tumour necrosis factor α, interleukin 1, and interleukin 6 in meningococcal meningitis. J Exp Med 1983; 158: 1859-1867.

38. Movat HZ, Cybulsky MI, Neutrophil migration and microvascular injury. Role of chemotaxins, endotoxin, interleukin 1 and tumour necrosis factor α. J Med Microbiol 1987; 3: 153-157.

39. Ringler DJ, Walsh DG, MacKey JJ, McVieper RB, Hunt RD, Newman W. Sequential cys-thymopoietin localization, leukocyte-endothelial cell adhesion molecule (CAM) expression, and leucocyte typing in rhesus monkeys receiving intradermal LPS. FASEB J 1992; 6: A1899.

ACKNOWLEDGEMENTS. The authors are grateful for gifts of cytokines from Dr. D. Urvil (Immunex Corp.), Dr. M. Stepphard (Genentech Inc.), Dr. R. C. Thompson (Sinaengen Inc.), Dr. C. Druff (Tufts University), and from Sandor Pharmaceuticals, which helped make this study possible. We are also grateful for the excellent technical assistance of Ms. S. Dunlop and Mr. K. MacLeod, Ms. J. Stolz, and Ms. D. Randall for manuscript preparation.

This work was supported by grants MA-7684 and MA-8575 from the Medical Research Council of Canada.

Received 27 July 1992: accepted 8 August 1992